DRD1

Dopamine receptor D₁, also known as DRD1. It is one of the two types of D₁-like receptor family receptors D₁ and D₅. It is a protein that in humans is encoded by the DRD1 gene.

Tissue distribution

D₁ receptors are the most abundant kind of dopamine receptor in the central nervous system.

Northern blot and in situ hybridization show that the mRNA expression of DRD1 is highest in the dorsal striatum ( caudate and putamen) and ventral striatum (nucleus accumbens and olfactory tubercle).

Lower levels occur in the basolateral amygdala, cerebral cortex, septum, thalamus, and hypothalamus.

The DRD1 gene expresses primarily in the caudate putamen in humans, and in the caudate putamen, the nucleus accumbens and the olfactory tubercle in mouse.

Structure

The dopamine receptor D1 (D1R) is a Gs-coupled GPCR characterized by a canonical seven-transmembrane (TM) helical domain, with a ligand-binding pocket located extracellularly and a cytoplasmic G-protein interaction interface. Cryo-EM and X-ray crystallography studies reveal that agonist binding induces conformational changes, including outward movement of TM6 and extension of TM5 by two helical turns, facilitating engagement with the Gαs subunit.

Agonist interact with extracellular loop 2 and extracellular regions of trans-membrane helices 2, 3, 6, and 7. Interactions between catechol-based agonists and three trans-membrane serine residues including S198^5.42, S199^5.43, and S202^5.46 function as microswitches that are essential for receptor activation.

The ligand-binding pocket accommodates both catechol (e.g., dopamine, SKF81297) and non-catechol agonists, with selectivity influenced by residues like V317^7.39 and W321^7.43 in TM7, which form hydrophobic interactions rather than the polar contacts seen in β2-adrenergic receptors. Non-catechol agonists bind in an extended conformation, spanning the orthosteric site to extracellular loop 2 (ECL2), leveraging unique pocket topology for D1R specificity. Structural comparisons with D2R highlight divergent cytoplasmic features—D1R’s elongated TM5 and larger Gs interface (~1,520 Ų) contrast with D2R’s Gi-selective coupling, underpinning functional specificity. These insights provide templates for designing selective therapeutics targeting dopaminergic pathways.

Function

D₁ receptors regulate the memory, learning, and the growth of neurons, also is used in the reward system and locomotor activity, mediating some behaviors and modulating dopamine receptor D₂-mediated events.

They play a role in addiction by facilitating the gene expression changes that occur in the nucleus accumbens during addiction.

They are Gs coupled and can stimulate neurons by activation of cyclic AMP-dependent protein kinase.

Ligands

There are a number of ligands selective for the D₁ receptors. To date, most of the known ligands are based on dihydrexidine or the prototypical benzazepine partial agonist SKF-38393 (one derivative being the prototypical antagonist SCH-23390). D₁ receptor has a high degree of structural homology to another dopamine receptor, D₅, and they both bind similar drugs. As a result, none of the known orthosteric ligands is selective for the D₁ vs. the D₅ receptor, but the benzazepines generally are more selective for the D₁ and D₅ receptors versus the D₂-like family. Some of the benzazepines have high intrinsic activity whereas others do not. In 2015 the first positive allosteric modulator for the human D₁ receptor was discovered by high-throughput screening.

Agonists

Several D₁ receptor agonists are used clinically. These include apomorphine, pergolide, rotigotine, and terguride. All of these drugs are preferentially D₂-like receptor agonists. Fenoldopam is a selective D₁ receptor partial agonist that does not cross the blood-brain-barrier and is used intravenously in the treatment of hypertension. Dihydrexidine and adrogolide (ABT-431) (a prodrug of A-86929 with improved bioavailability) are the only selective, centrally active D₁-like receptor agonists that have been studied clinically in humans. The selective D₁ agonists give profound antiparkinson effects in humans and primate models of PD, and yield cognitive enhancement in many preclinical models and a few clinical trials. The most dose-limiting feature is profound hypotension, but the clinical development was impeded largely by lack of oral bioavailability and short duration of action. In 2017, Pfizer made public information about pharmaceutically-acceptable non-catechol selective D₁ agonists that are in clinical development.

List of D₁ receptor agonists

* Dihydrexidine derivatives
** A-86929 full agonist with 14-fold selectivity for D₁-like receptors over D₂
** Dihydrexidine full agonist with 10-fold selectivity for D₁-like receptors over D₂ that has been in Phase IIa clinical trials as a cognitive enhancer. It also showed profound antiparkinson effects in MPTP-treated primates, but caused profound hypotension in one early clinical trial in Parkinson's disease. Although dihydrexidine has significant D₂ properties, it is highly biased at D₁ receptors and was used for the first demonstration of functional selectivity with dopamine receptors.
** Dinapsoline full agonist with 5-fold selectivity for D₁-like receptors over D₂
** Dinoxyline full agonist with approximately equal affinity for D₁-like and D₂ receptors
** Doxanthrine full agonist with 168-fold selectivity for D₁-like receptors over D₂
* Benzazepine derivatives
** SKF-81297 200-fold selectivity for D₁ over any other receptor
** SKF-82958 57-fold selectivity for D₁ over D₂
** SKF-38393 very high selectivity for D₁ with negligible affinity for any other receptor
** Clozapine partial agonist at D₁-like receptors
** Fenoldopam highly selective peripheral D₁ receptor partial agonist used clinically as an antihypertensive
** 6-Br-APB 90-fold selectivity for D₁ over D₂
** Trepipam (SCH-12679)
* Others
** Stepholidine alkaloid with D₁ agonist and D₂ antagonist properties, showing antipsychotic effects
** A-68930
** A-77636
** CY-208,243 high intrinsic activity partial agonist with moderate selectivity for D₁-like over D₂-like receptors, member of ergoline ligand family like pergolide and bromocriptine.
** SKF-89145
** SKF-89626
** 7,8-Dihydroxy-5-phenyl-octahydrobenzo 'h''soquinoline extremely potent, high-affinity full agonist
** Cabergoline weak D₁ agonism, highly selective for D₂, and various serotonin receptors
** Pergolide (similar to cabergoline) weak D₁ agonism, highly selective for D₂, and various serotonin receptors
** A photoswitchable agonist of D₁-like receptors (azodopa) has been described that allows reversible control of dopaminergic transmission in wildtype animals.

Positive allosteric modulators

* DETQ PAM
* Glovadalen (UCB-0022) selective PAM, in phase 2 studies for Parkinson's disease
* Mevidalen (LY-3154207) potent and subtype selective PAM, in phase 2 studies for Lewy body dementia.

Antagonists

Many typical and atypical antipsychotics are D₁ receptor antagonists in addition to D₂ receptor antagonists. But asenapine has shown stronger D₁ receptor affinity compared to other antipsychotics. No other D₁ receptor antagonists have been approved for clinical use. Ecopipam is a selective D₁-like receptor antagonist that has been studied clinically in humans in the treatment of a variety of conditions, including schizophrenia, cocaine abuse, obesity, pathological gambling, and Tourette's syndrome, with efficacy in some of these conditions seen. The drug produced mild-to-moderate, reversible depression and anxiety in clinical studies however and has yet to complete development for any indication.

List of D₁ receptor antagonists

* Berupipam (NNC 22-0010)
* Ecopipam (SCH-39,166) a selective D₁/D₅ antagonist that was being developed as an anti-obesity medication but was discontinued However, it has showed promise in reducing stuttering and is currently in Phase 2 Trials for this purpose
* NNC 01-0687 (ADX-10061)
* Odapipam (NNC 01-0756)
* SCH-23,390 100-fold selectivity for D₁ over D₅

Protein–protein interactions

Dopamine receptor D₁ has been shown to interact with:

* COPG2
* COPG
* DNAJC14

Receptor oligomers

The D₁ receptor forms heteromers with the following receptors: dopamine D₂ receptor, dopamine D₃ receptor, histamine H₃ receptor, μ opioid receptor, NMDA receptor, and adenosine A₁ receptor.
Dopamine D₁ receptor hetero-oligomers
/ref>
* D₁–D₂ receptor complex
* D₁− H₃− NMDAR receptor complex a target to prevent neurodegeneration
* D₁– D3 receptor complex
* D₁– NMDAR receptor complex
* D₁– A₁ receptor complex

See also

* Dopamine receptor

References

External links

*
*

{{Dopaminergics

Dopamine receptors